A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) (CTII-nCoV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04341389

Recruitment Status : Completed

First Posted : April 10, 2020

Last Update Posted : May 24, 2023

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

CanSino Biologics Inc.

Jiangsu Province Centers for Disease Control and Prevention

Hubei Provincial Center for Disease Control and Prevention

Zhongnan Hospital

Information provided by (Responsible Party):

Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	November 30, 2020
Actual Study Completion Date :	December 31, 2020

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20.

To Top